196 related articles for article (PubMed ID: 31742407)
1. Synthesis and Characterization of Long-Acting Darunavir Prodrugs.
Banoub MG; Bade AN; Lin Z; Cobb D; Gautam N; Dyavar Shetty BL; Wojtkiewicz M; Alnouti Y; McMillan J; Gendelman HE; Edagwa B
Mol Pharm; 2020 Jan; 17(1):155-166. PubMed ID: 31742407
[TBL] [Abstract][Full Text] [Related]
2. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
[TBL] [Abstract][Full Text] [Related]
4.
Hijazi K; Iannelli F; Cuppone AM; Desjardins D; Caldwell A; Dereuddre-Bosquet N; Scala C; Smith KA; Mukhopadya I; Frank B; Gwozdz G; Santoro F; Grand RL; Pozzi G; Kelly C
Mol Pharm; 2020 Mar; 17(3):852-864. PubMed ID: 32017579
[TBL] [Abstract][Full Text] [Related]
5. A long acting nanoformulated lamivudine ProTide.
Smith N; Bade AN; Soni D; Gautam N; Alnouti Y; Herskovitz J; Ibrahim IM; Wojtkiewicz MS; Dyavar Shetty BL; McMillan J; Gendelman HE; Edagwa B
Biomaterials; 2019 Dec; 223():119476. PubMed ID: 31525692
[TBL] [Abstract][Full Text] [Related]
6. Creation of a long-acting rilpivirine prodrug nanoformulation.
Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a long acting nanoformulated emtricitabine ProTide.
Soni D; Bade AN; Gautam N; Herskovitz J; Ibrahim IM; Smith N; Wojtkiewicz MS; Dyavar Shetty BL; Alnouti Y; McMillan J; Gendelman HE; Edagwa BJ
Biomaterials; 2019 Nov; 222():119441. PubMed ID: 31472458
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
[TBL] [Abstract][Full Text] [Related]
9. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
Rolle CP; Marquez O; Nguyen V; Hinestrosa F; DeJesus E
Int J STD AIDS; 2020 Sep; 31(10):958-966. PubMed ID: 32698728
[TBL] [Abstract][Full Text] [Related]
12. Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
Höring S; Löffler B; Pletz MW; Rößler S; Weis S; Schleenvoigt BT
Infection; 2018 Oct; 46(5):599-605. PubMed ID: 29961209
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a long-acting nanoformulated abacavir prodrug.
Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
[TBL] [Abstract][Full Text] [Related]
14. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
[TBL] [Abstract][Full Text] [Related]
15. Darunavir/cobicistat once daily for the treatment of HIV.
Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
[TBL] [Abstract][Full Text] [Related]
16. Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.
Nagano D; Araki T; Yanagisawa K; Ogawa Y; Gohda F; Uchiumi H; Handa H; Nakamura T; Yamamoto K
Eur J Clin Pharmacol; 2018 Aug; 74(8):1055-1060. PubMed ID: 29721582
[TBL] [Abstract][Full Text] [Related]
17. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
[No Abstract] [Full Text] [Related]
18. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
[TBL] [Abstract][Full Text] [Related]
19. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
20. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Huhn GD; Sigman A; Livak B
Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
